MedTrace Logo

Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination

NCT07154810 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2025-09-04

No results posted yet for this study

Summary

The goal of this clinical trial is to further observe and learn if the SpyGlass Pharma Bimatoprost Implant System / IOL Combination works to treat cataracts and either ocular hypertension or glaucoma. It will also further observe and learn about the safety of the Bimatoprost Implant System / IOL Combination. The main questions it aims to answer are:

* Does the Bimatoprost Implant System / IOL Combination continue lower the pressure inside the eye to treat ocular hypertension or glaucoma long term?
* Does the Bimatoprost Implant System / IOL Combination continue to correct vision after cataract surgery long term?
* What long term medical problems do participants have when treated with the Bimatoprost Implant System / IOL Combination?

Conditions

Sponsors & Collaborators

  • SpyGlass Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Sr. Director, Clinical Affairs · SpyGlass Pharma, Inc.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-16
Primary Completion
2031-04-14
Completion
2031-04-14

Countries

  • Honduras

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07154810 on ClinicalTrials.gov